Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su)

References

• Eshleman E, Shahzad A, Cohrs RJ. Varicella zoster virus latency. Future Virol 2011; 6:341 - 55; http://dx.doi.org/10.2217/fvl.10.90; PMID: 21695042
   PubMed Web of Science ®Google Scholar
• Varicella vaccines. WHO position paper. Wkly Epidemiol Rec 1998; 73:241 - 8; PMID: 9715106
   PubMedGoogle Scholar
• Toyama N, Shiraki K, Society of the Miyazaki Prefecture Dermatologists. Epidemiology of herpes zoster and its relationship to varicella in Japan: A 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J Med Virol 2009; 81:2053 - 8; http://dx.doi.org/10.1002/jmv.21599; PMID: 19856466
   PubMed Web of Science ®Google Scholar
• Chapman RS, Cross KW, Fleming DM. The incidence of shingles and its implications for vaccination policy. Vaccine 2003; 21:2541 - 7; http://dx.doi.org/10.1016/S0264-410X(03)00034-3; PMID: 12744889
   PubMed Web of Science ®Google Scholar
• Gonzalez Chiappe S, Sarazin M, Turbelin C, Lasserre A, Pelat C, Bonmarin I, et al. Herpes zoster: Burden of disease in France. Vaccine 2010; 28:7933 - 8; http://dx.doi.org/10.1016/j.vaccine.2010.09.074; PMID: 20946861
   PubMed Web of Science ®Google Scholar
• Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82:1341 - 9; http://dx.doi.org/10.4065/82.11.1341; PMID: 17976353
   PubMed Web of Science ®Google Scholar
• Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57:RR-5 1 - 30, quiz CE2-4; PMID: 18528318
   PubMedGoogle Scholar
• Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010; 48:Suppl 1 S2 - 7; http://dx.doi.org/10.1016/S1386-6532(10)70002-0; PMID: 20510263
   PubMed Web of Science ®Google Scholar
• Schmader KE, Levin MJ, Gnann JW Jr., McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922 - 8; http://dx.doi.org/10.1093/cid/cir970; PMID: 22291101
   PubMed Web of Science ®Google Scholar
• Murray AV, Reisinger KS, Kerzner B, Stek JE, Sausser TA, Xu J, et al. Safety and tolerability of zoster vaccine in adults ≥60 years old. Hum Vaccin 2011; 7:1130 - 6; http://dx.doi.org/10.4161/hv.7.11.17982; PMID: 22048110
   PubMed Web of Science ®Google Scholar
• Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc 2009; 84:274 - 80; http://dx.doi.org/10.4065/84.3.274; PMID: 19252116
   PubMed Web of Science ®Google Scholar
• Andrei G, Snoeck R. Emerging drugs for varicella-zoster virus infections. Expert Opin Emerg Drugs 2011; 16:507 - 35; http://dx.doi.org/10.1517/14728214.2011.591786; PMID: 21699441
   PubMed Web of Science ®Google Scholar
• Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis 2010; 51:197 - 213; http://dx.doi.org/10.1086/653605; PMID: 20550454
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al, Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271 - 84; http://dx.doi.org/10.1056/NEJMoa051016; PMID: 15930418
   PubMed Web of Science ®Google Scholar
• Garçon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007; 6:723 - 39; http://dx.doi.org/10.1586/14760584.6.5.723; PMID: 17931153
   PubMed Web of Science ®Google Scholar
• Garçon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011; 10:471 - 86; http://dx.doi.org/10.1586/erv.11.29; PMID: 21506645
   PubMed Web of Science ®Google Scholar
• Grose C. Glycoproteins encoded by varicella-zoster virus: biosynthesis, phosphorylation, and intracellular trafficking. Annu Rev Microbiol 1990; 44:59 - 80; http://dx.doi.org/10.1146/annurev.mi.44.100190.000423; PMID: 2174668
   PubMed Web of Science ®Google Scholar
• Grahn A, Studahl M, Nilsson S, Thomsson E, Bäckström M, Bergström T. Varicella-zoster virus (VZV) glycoprotein E is a serological antigen for detection of intrathecal antibodies to VZV in central nervous system infections, without cross-reaction to herpes simplex virus 1. Clin Vaccine Immunol 2011; 18:1336 - 42; http://dx.doi.org/10.1128/CVI.05061-11; PMID: 21697341
   PubMedGoogle Scholar
• Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E, et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis 2012; 206:1280 - 90; http://dx.doi.org/10.1093/infdis/jis497; PMID: 22872734
   PubMed Web of Science ®Google Scholar
• Chlibek R, Smetana J, Pauksens K, Van den Hoek A, Richardus JH, Wachter J, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults. Presented at the 37th Annual International Herpesvirus Workshop (IHW), Canada, August 4–9, 2012. Available at: http://www.herpesvirusworkshop.com/2012/. Accessed: November 2nd, 2012.
   Google Scholar
• Clark TG, Cassidy-Hanley D. Recombinant subunit vaccines: potentials and constraints. Dev Biol (Basel) 2005; 121:153 - 63; PMID: 15962478
   PubMedGoogle Scholar